Clinical trials: Thinning Hair
Alopecia Areata, Vitiligo
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
This is a multi-center, parallel-group, open-label, randomized, Phase 1b study to explore the safety, clinical activity, pharmacokinetics and pharmacodynamics of DR-01 in adults with Alopecia Areata or Vitiligo.
- Trial name
- NCT06602232
- Testing
- DR-01
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 81 people
- Sponsor
- Dren Bio
Alopecia Areata
A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
Part A is a randomized, double-blind, placebo-controlled, multi-center Proof-of-Concept (POC) Trial in subjects with severe Alopecia Areata. All participants in Part A have completed participation.
- Trial name
- SIGNAL-AA (NCT06018428)
- Testing
- bempikibart (ADX-914)
- Where
- 33 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- Q32 Bio Inc.
Androgenetic Alopecia, Coronavirus Disease 2019
Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).
Coronavirus disease 2019 (COVID-19) can cause variable symptoms ranging from mild common cold-like symptoms to severe life threatening pneumonia.
- Conditions
- Androgenetic Alopecia, Coronavirus Disease 2019, Covid19, Male Pattern Baldness
- Trial name
- NCT04898166
- Where
- Pakistan
- Volunteers
- 300 people
- Sponsor
- Syeda Mahanum Ali
Alopecia, Androgenetic
Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia
The purpose of this study is to confirm the clinical efficacy and the safety of P-3074 in participants with androgenetic alopecia.
- Trial name
- NCT03004469
- Testing
- P-3074, Finasteride, P-3074 Vehicle
- Where
- 46 sites in Belgium, Germany and 3 more
- Volunteers
- 458 people
- Sponsor
- Polichem S.A.
Telogen Effluvium
Efficacy and Safety of Millet Seed Extract in Telogen Effluvium Treatment
This is a randomized, double-blind, controlled clinical trial investigating the efficacy and safety of millet seed extract capsules in treating telogen effluvium in female patients.
- Trial name
- NCT07348120
- Testing
- Millet Seed Extract group, Biotin group
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Kasr El Aini Hospital
Chemotherapy Induced Alopecia, Chemotherapy Side Effects
Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia
Clinical Study of DA-020 as a Treatment for Chemotherapy Induced Alopecia
- Trial name
- NCT07397325
- Testing
- DA-020, DA-020 and Hyperforin
- Where
- 2 sites in Brazil, Italy
- Volunteers
- 60 people
- Sponsor
- Applied Biology, Inc.
Hair Thinning, Hair Loss
The Effect of 24-week Dietary Intake of Food Supplements on Hair
Purpose of this randomized, double-blind, placebo-controlled study will be to evaluate whether the daily use of novel dietary supplements over 24 weeks is able strengthen and promote growth of hairs, improve their density and…
- Trial name
- TO-HAIR (NCT06174441)
- Testing
- Investigational product 1 (CPMSM), Investigational product 2 (HC+)
- Where
- Slovenia
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- VIST - Faculty of Applied Sciences
Alopecia Totalis
Efalizumab in the Treatment of Alopecia, Phase II
Determine the effect that treatment with efalizumab has on scalp hair re-growth in younger adults affected by severe variants of alopecia areata, including alopecia totalis, alopecia universalis, and severe ophiasis variants.
- Trial name
- NCT00746980
- Testing
- efalizumab
- Sponsor
- Northwestern University
Alopecia Areata
Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata
The objective of this study is to assess the safety and efficacy of Tofacitinib in treating patients with extensive and recalcitrant Alopecia Areata (AA), along with to evaluate the economic impact of the patients that may be…
- Trial name
- NCT03800979
- Testing
- Tofacitinib
- Where
- Thailand
- Volunteers
- 19 people
- Sponsor
- Institute of Dermatology, Thailand
Hair Thinning
Efficacy of the New Viviscal Professional Strength Oral Supplement in Females With Thinning Hair
The New Viviscal Professional Strength is an oral food supplement specifically designed to promote hair growth for women suffering from temporary thinning hair. It does not contain hormones, drugs or industry by-products.
- Trial name
- NCT02302053
- Testing
- New Viviscal Professional Supplement
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ablon Skin Institute Research Center
Androgenetic Alopecia
Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction
Androgenetic alopecia is the most common type of alopecia in both men and women. About 80 % of Caucasian men and 40-50 % of Caucasian women are affected by androgenetic alopecia.
- Trial name
- NCT03388840
- Testing
- Adipose derived stem cells suspention, Platelet rich plasma
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Assiut University
Androgenetic Alopecia
Efficacy of Nutrition Supplement for Treatment of Men With Hair Loss
HCap Formula is composed of medicinal plants, vitamins and minerals. The purpose of this study is to evaluate the efficacy of HCap Formula, a nutrition supplement for promoting hair growth in men with tendencies for hair loss.
- Trial name
- NCT02150187
- Testing
- HCap Formula
- Where
- Israel
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Family Marketing
Androgenic Alopecia
Topical 2-Deoxy-D-ribose Hydrogel Versus Minoxidil 5% Solution for Androgenetic Alopecia
Androgenetic alopecia is a common form of hair loss that can affect quality of life. This randomized controlled trial aims to evaluate the efficacy and safety of topical 2-Deoxy-D-ribose (2dDR) hydrogel compared with topical…
- Trial name
- NCT07502976
- Testing
- Topical 2-Deoxy-D-ribose Hydrogel, Topical Minoxidil 5% Solution
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Kasr El Aini Hospital
Androgenetic Alopecia
Safety and Efficacy Study of Human Autologous Hair Follicle Cells to Treat Androgenetic Alopecia
The primary purpose of this study is to assess the safety of performing injections of human autologous hair follicle cells. The study will also measure the impact these injections will have on hair growth.
- Trial name
- NCT01286649
- Testing
- Human autologous hair follicle cells, Cell medium
- Where
- Georgia
- Volunteers
- 19 people
- Sponsor
- TrichoScience Innovations, Inc.
Female Pattern Alopecia
The Efficacy in Treatment of Female Pattern Hair Loss Using 5% Minoxidil Solution Combinded With Zinc Supplement
Zinc supplement is a popular trace element gave to Female pattern hair loss (FPHL) patient. But the type of patient, efficacy, and side effect in detail of zinc supplement are not well characterized.
- Trial name
- NCT01662089
- Testing
- 15 mg Chelate zinc supplement
- Where
- Thailand
- Volunteers
- 20 people
- Sponsor
- Siriraj Hospital
Alopecia
A Clinical Traial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of CKD-843
A Clinical Traial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of CKD-843
- Trial name
- NCT04805606
- Testing
- CKD-843 A, CKD-843 B, CKD-843-R
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Alopecia Areata
Aldara for the Treatment of Extensive Alopecia Areata
We propose to examine the efficacy and tolerability of Aldara Cream 5% for the treatment of extensive alopecia areata. Aldara is a immune-response modifier.
- Trial name
- NCT00177021
- Testing
- Aldara Cream 5%
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hordinsky, Maria K., MD
Chemotherapy Induced Alopecia
The Lily Device Trial
The goal of this clinical trial is to test if the Lily Device works to reduce chemotherapy induced hair loss in patients. It will also learn about the safety of the Lily Device.
- Trial name
- PREVAIL (NCT06786078)
- Testing
- Lily Device
- Where
- 5 sites in United States
- Volunteers
- 85 people
- Sponsor
- Luminate Medical, Inc.
Androgenic Alopecia
Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality
The study aims to assess the efficacy and safety of Keravive by Hydrafacial treatments and Keravive Peptide Spray for scalp health and enhancing hair quality in patients with androgenic alopecia.
- Trial name
- NCT06112782
- Testing
- Keravive by Hydrafacial Treatments
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Beauty Health
Androgenetic Alopecia
A Study to Evaluate the Efficacy and Safety of AD-208
The purpose of this study is to evaluate the efficacy and safety of AD-208.
- Trial name
- NCT04825561
- Testing
- AD-208, AD-2081
- Where
- South Korea
- Volunteers
- 139 people
- Sponsor
- Addpharma Inc.